Overview

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria

Status:
COMPLETED

Trial end date:
2025-02-21

Target enrollment:

Participant gender:

Summary

This is Cohort A1 of the Platform study (NCT05750628) to evaluate the efficacy and safety of INE963 in participants with uncomplicated Plasmodium falciparum malaria.

Phase:

PHASE2

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

INE963